Country-by-country analysis of medical cannabis programmes across 32 European markets — legal framework, patient access, prescribing pathways, GMP requirements, reimbursement status and market access for international suppliers.
Enter your email to receive the complete formatted PDF.
This publication provides a structured country-by-country analysis of medical cannabis programmes across 32 European jurisdictions. For each country, we cover the legal framework, prescribing pathway, patient access, GMP requirements for product supply, reimbursement status and the key regulatory authority.
This is a companion to the ECI Regulatory Map (available at ec-institute.com/map.html), which provides an interactive overview of the same data.
Cannabis regulation is evolving rapidly across Europe. This publication reflects the regulatory position as of July 2026. Readers should verify current requirements with the relevant national authority before making commercial decisions.
Framework: Cannabis rescheduled from BtMG Schedule I to a controlled medicinal substance under the Cannabisgesetz (CanG) April 2024. Medical cannabis prescribable by any licensed physician for any indication where the physician considers it appropriate.
Prescribing: Any licensed physician. No specialist restriction. Prescription on BtM-Rezept (narcotic prescription form).
Patient numbers: Estimated 350,000–450,000 active patients (mid-2026).
GMP requirement: EU GMP mandatory for all pharmaceutical cannabis products. BfArM issues import permits. Product specifications must meet BfArM quality requirements.
Reimbursement: Statutory health insurance (GKV) coverage for serious conditions where conventional treatment has failed. Private insurance coverage varies. Self-pay market significant.
Authority: BfArM (Federal Institute for Drugs and Medical Devices).
Market access: Import-dependent supplemented by domestic production. Major import sources: Netherlands, Portugal, Denmark, Canada, Australia, Colombia.
Framework: Medical cannabis programme since 2003 under Opiumwet. State monopoly production by Bedrocan under Bureau voor Medicinale Cannabis (BMC) oversight.
Prescribing: Any physician. Dispensed through licensed pharmacies.
GMP requirement: Bedrocan operates under EU GMP; all product certified to pharmaceutical standard.
Reimbursement: Limited — specific indications only. Primarily out-of-pocket.
Authority: IGJ (Healthcare and Youth Inspectorate); BMC (Bureau voor Medicinale Cannabis).
Market access: Closed domestic market served exclusively by Bedrocan. Export to approved countries.
Framework: Medical cannabis framework established 2018 (Law 33/2018). Medicines agency Infarmed oversees licensing and GMP certification.
Prescribing: Specialist physicians in licensed facilities. Patient access through hospital pharmacy.
GMP requirement: EU GMP mandatory. Infarmed issues GMP certificates and conduct inspections.
Reimbursement: Limited coverage. Primarily private.
Authority: Infarmed (National Authority of Medicines and Health Products).
Market access: Growing domestic prescribing market; Portugal primarily an export-oriented manufacturing jurisdiction supplying Germany and other EU markets.
Framework: Medical cannabis legalised 2007; regulations updated 2017. ISS (National Health Institute) oversees quality; pharmaceutical cannabis dispensed through hospital pharmacies.
Prescribing: Any physician for approved indications: neuropathic pain, spasticity, nausea/vomiting, anorexia/cachexia, glaucoma, Tourette syndrome.
GMP requirement: EU GMP mandatory for imported product; AIFA oversight.
Reimbursement: Regional variation — some regions reimburse for approved indications; others require full private payment.
Authority: AIFA (Agenzia Italiana del Farmaco); ISS (Istituto Superiore di Sanità).
Market access: Imported product from Netherlands, Canada and licensed EU manufacturers. Military Pharmaceutical Chemistry Institute (SIMC) produces limited domestic supply.
Framework: Medical cannabis pilot launched 2021; extended 2023 and 2025. Full programme pending legislative approval.
Prescribing: Specialist physicians only (under pilot conditions).
Indications: Treatment-resistant chronic pain; certain epilepsies; palliative care; MS spasticity; chemotherapy-related nausea.
GMP requirement: EU GMP mandatory. ANSM oversight.
Reimbursement: Free under pilot (government-funded). Reimbursement status for full programme TBD.
Authority: ANSM (Agence Nationale de Sécurité du Médicament).
Market access: Imported product during pilot. Domestic manufacturing under development.
Framework: No national medical cannabis programme. Magistral preparations (pharmacy-compounded) available for specific patients under physician supervision. Regional variation significant.
Prescribing: Magistral prescription through specialist physician.
GMP requirement: Pharmacy compounding standards apply; not EU GMP for finished products.
Reimbursement: No.
Authority: AEMPS (Agencia Española de Medicamentos y Productos Sanitarios).
Market access: Limited. National programme under political discussion but not enacted as of July 2026.
Framework: Medical cannabis legal since 2013. Framework revised 2022. Domestic cultivation and processing licensed.
Prescribing: Specialist physicians in approved medical centres.
GMP requirement: EU GMP required for pharmaceutical products; SÚKL (State Institute for Drug Control) oversight.
Reimbursement: No statutory reimbursement.
Authority: SÚKL (Státní ústav pro kontrolu léčiv).
Market access: Domestic and import. Growing market with established prescribing infrastructure.
Framework: Medical cannabis legal since 2017. Imported pharmaceutical-grade products only — no domestic manufacturing.
Prescribing: Any physician. Indication not restricted.
GMP requirement: EU GMP mandatory for imported product.
Reimbursement: No statutory reimbursement. Private pay only.
Authority: GIF (Chief Pharmaceutical Inspectorate); URPL (Office for Registration of Medicinal Products).
Market access: Pure import market. Growing prescribing base; significant unmet demand. Key opportunity for EU GMP exporters.
Framework: Medical cannabis legal since 2017; export framework established 2018. Greece is licensing cultivation and processing for export as well as domestic supply.
Prescribing: Approved indications through specialist centres.
GMP requirement: EU GMP required for pharmaceutical products; EOF (National Organization for Medicines) oversight.
Reimbursement: Limited.
Authority: EOF (Εθνικός Οργανισμός Φαρμάκων).
Market access: Developing domestic market; Greece positioned as export-oriented producer for German and broader EU markets.
The following markets have frameworks in place but prescribing volumes remain very low, reimbursement is absent and market access for international suppliers is limited or undeveloped: Romania, Hungary, Croatia, Slovenia, Estonia, Latvia, Lithuania, Bulgaria, Slovakia, Serbia, Switzerland (non-EU, own framework), Norway (EEA), Denmark, Sweden, Finland, Austria, Belgium, Luxembourg, Ireland.
These markets represent medium-term (3–5 year) opportunities as programmes mature, prescribing infrastructure develops and patient awareness increases. Several — notably Switzerland, Denmark, Ireland and Belgium — have frameworks sufficiently developed that earlier market entry may be warranted for operators with regulatory expertise and appetite for early-stage market development.
Subscribe for new publications monthly.